The Know ALL website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know ALL cannot guarantee the accuracy of translated content. Know ALL and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
What is MRD, and why is it important in acute lymphoblastic leukemia?
Sebastian Giebel
March 23, 2022
During the ESH 3rd How to Diagnose and Treat Acute Leukaemias, Know ALL spoke with Sebastian Giebel, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice, PL. We asked, What is measurable residual disease (MRD), and why is it important in acute lymphoblastic leukemia?
Giebel begins by discussing detection methods, including flow cytometry or molecular techniques which are used to precisely monitor responses. He highlights the huge prognostic impact MRD can have for patients. Finally, he outlines the bispecific antibody blinatumomab, used as a therapy to eradicate MRD.
